Brief: Agenus Announces Updated Phase 1 Data On BOT/BAL Development In Metastatic MSS Colorectal Cancer
12/04/2024 15:01
April 12 (Reuters) - Agenus Inc AGEN.O :
* AGENUS ANNOUNCES UPDATED PHASE 1 DATA AND PROGRESS ON
BOT/BAL
DEVELOPMENT IN METASTATIC MSS COLORECTAL CANCER
* AGENUS INC - UPDATED PHASE 1 DATA DEMONSTRATE A 12-MONTH
OVERALL
SURVIVAL (OS) OF 71% AND 18-MONTH OS OF 62%
* AGENUS INC - COMPANY PLANS TO DISCUSS ENCOURAGING PHASE 2
INTERIM RESULTS WITH FDA
* AGENUS INC - COMPANY PLANS TO SUBMIT PHASE 2 DATA TO A
MAJOR
MEDICAL CONFERENCE IN SECOND HALF OF 2024
Source text for Eikon: ID:nBwgTh2ya
Further company coverage: AGEN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Agenus
See all newsBrief: Agenus Reports 72% Of Patients With Locally Advanced Dmmr Colon Cancer Had No Cancer Remaining At Surgery Following Six Weeks Of Bot+Bal In Phase 2 Neoasis Study At Esmo 2026
Brief: Armenia Grants First Marketing Authorizations For Agenus’ Bot+Bal In Previously Treated Mss Metastatic Colorectal Cancer
Brief: Agenus - Unit Enters Second Loan Modification Agreement With Ocean 1181 On Aug 12, 2026 - SEC Filing
Agenus Inc reports results for the quarter ended June 30 - Earnings Summary
Agenus Q2 revenue rises on access and royalty income